tbuckley/cabot-search huggingface dataset:
Building Stronger Online Communities Through the Creation of Facebook-Integrated Health Applications
Authors: Douglas B. Mogul, Paul G. Nagy, John F. P. Bridges
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
The management of anal warts
Authors: R. Maw
Journal: BMJ (2000)

The incidence of condylomata acuminata, commonly known as anogenital warts, is increasing. In the United Kingdom it is the most common sexually transmitted disease; in 1997 over 50 000 new cases were reported, accounting for 22% of all diagnoses made in genitourinary medicine clinics.1 In the United States an estimated 1% of adults who are sexually active have lesions.2 These benign warts are caused by human papillomavirus; genotypes 6 and 11 are found in over 90% of cases.3 However, some patients are concurrently infected with oncogenic types of the virus, principally genotypes 16 and 18, which may induce multifocal anogenital intraepithelial neoplasia and cervical cancer.4 Although people with anogenital warts present to many different disciplines guidelines for management have recently been published by the Medical Society for the Study of Venereal Diseases of the United Kingdom and the European Course on Human Papilloma Virus Associated Pathology Group. 5 6

These guidelines conform to recommendations as for a Cochrane review and focus on sharing …
DNA複製:DONSON変異は複製フォークの安定性を失わせ,小頭性小人症を引き起こす
Authors: Reynolds John J, Higgs Martin R, Zlatanou Anastasia, Vernet Audrey, Mottram Rachel M A, Brean Alexander, Taylor A Malcolm R, Stewart Grant S, Bicknell Louise S, Carroll Paula, Murray Jennie E, Leitch Andrea, Murina Olga, Tarnauskaite Zygimante, Von Kriegsheim Alex, Logan Clare, Challis Rachel C, Reijns Martin A M, Jackson Andrew P, Shaheen Ranad, Maddirevula Sateesh, Almoisheer Agaadir, Alsaif Hessa S, Alkuraya Fowzan S, Papadopoulos Dimitrios K, Skouloudaki Kassiani, Tomancak Pavel, Wessel Sarah R, Cortez David, Bye Hannah, Amar Ariella, Prescott Natalie J, Simpson Michael A, Mathew Christopher G, Li Yun, Yigit Goekhan, Bober Michael B, Duker Angela, Faqeih Eissa, Seidahmed Mohammed Zain, AL Tala Saeed, Alswaid Abdulrahman, Ahmed Saleem, Al‐Aama Jumana Yousuf, Altmueller Janine, Nuernberg Peter, AL Balwi Mohammed, Brady Angela F, Chessa Luciana, Cox Helen, Fischetto Rita, Heller Raoul, Henderson Bertram D, Hobson Emma, Percin E Ferda, Peron Angela, Spaccini Luigina, Quigley Alan J, Thakur Seema, Wise Carol A, Yoon Grace, Alnemer Maha
Journal: Nature Genetics (2017)
Hematopoietic stem cell involvement in BCR-ABL1–positive ALL as a potential mechanism of resistance to blinatumomab therapy
Authors: Inga Nagel, Marius Bartels, Johannes Duell, Hans-Heinrich Oberg, Sandra Ussat, Henrike Bruckmueller, Oliver Ottmann, Heike Pfeifer, Heiko Trautmann, Nicola Gökbuget, Almuth Caliebe, Dieter Kabelitz, Michael Kneba, Heinz-August Horst, Dieter Hoelzer, Max S. Topp, Ingolf Cascorbi, Reiner Siebert, Monika Brüggemann
Journal: Blood (2017)
Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma.
Authors: Mark R. Middleton, Neil Matthew Steven, Thomas Jeff Evans, Jeffrey R. Infante, Mario Sznol, Clive Mulatero, Omid Hamid, Alexander Noor Shoushtari, William Shingler, Andy Johnson, Sanjay Patel, Debbie Parker, David Krige, Cheryl McAlpine, Christina Marie Coughlin, Namir J Hassan, Bent K Jakobsen, Philippa Corrie
Journal: Journal of Clinical Oncology (2016)

3016 Background: T cell-based bispecific agents have shown activity in hematologic cancers, but solid tumor efficacy remains elusive. IMCgp100 is a bispecific biologic comprising an affinityenhanced TCR specific for gp100 and an anti-CD3 scFV. In vitro, IMCgp100 binds gp100+ melanoma cells causing redirection of cytotoxicity and induction of potent immune effects. Methods: The Phase I was conducted in HLA-A2+ pts with advanced melanoma, using a 3+3 design to define the MTD. Pts were treated with IMCgp100 (iv) weekly (QW, Arm 1) or daily (4QD3W, Arm 2) to evaluate safety, PK and efficacy. The recommended phase 2 regimen (RP2D-QW) was defined. Results: In the Ph I dose escalation,31 pts received doses from 5ng/kg to 900ng/kg. In arm 1 dose-limiting toxicity of gr 3 or 4 hypotension was seen and associated with rapid trafficking of peripheral lymphocytes to skin and tumor. The MTD was determined to be 600ng/kg QW. IMCgp100 has an approximately dose-proportional profile with a plasma T1/2 of 5-6 hrs at the RP2D; pharmacodynamic effects of chemokine/cytokine release and lymphocyte infiltration into tumors was observed over 2 days post dose. Frequent related AEs (any grade) include rash (100%), pruritus (64%), pyrexia (50%), and periorbital edema (46%). Gr 3 or 4 related AE were observed in the first 3 weeks and include rash (23%), hypotension (6%) and lymphopenia (8%). Hypotension observed at the first doses was consistent with chemokine release (CXCL9, CXCL10) and movement of lymphocytes into tissues and, rarely associated with cytokine release syndrome (IL-6, IL-10, IFNg). To mitigate risk of severe hypotension, flat dosing and an intra-patient escalation regimen of IMCgp100 were implemented. At the RP2D, 26 pts were evaluable for efficacy; confirmed PR were seen in 4 pts (2 uveal (UM) and 2 cutaneous (CM), including patients refractory to checkpoint agents) and 12 pts had SD. Of the 12 pts with SD, minor responses (>10% shrinkage) were seen in 3 pts. Conclusions: IMCgp100 is a first in class TCR anti-CD3 bispecific T cell redirector with a favorable safety profile and durable responses in melanoma (CM and UM). Ph II development in CM and UM is ongoing. Clinical trial information: NCT01211262.
Osteoporosis in patients with erythropoietic protoporphyria
Authors: M. Biewenga, R.H.S. Matawlie, E.C.H. Friesema, H. Koole-Lesuis, M. Langeveld, J.H.P. Wilson, J.G. Langendonk
Journal: British Journal of Dermatology (2017)

Background Erythropoietic protoporphyria (EPP) is a rare metabolic disease with painful photosensitivity due to protoporphyrin IX accumulation. Objectives To evaluate bone mineral density (BMD) and known osteoporosis risk factors in patients with EPP. Methods Patients with EPP attending the Erasmus MC outpatient clinic who had undergone BMD measurements were included. Plasma 25 hydroxy (OH) vitamin D, alkaline phosphatase, parathyroid hormone and total protoporphyrin IX levels were measured; information on lifestyle, sunlight exposure and a bone‐relevant physical exercise index [Bone Physical Activity Questionnaire (BPAQ) score] was obtained via questionnaires. BMD scores and the prevalence of osteopenia and osteoporosis in the EPP population were compared with a reference population. Results Forty‐four patients with EPP (23 female, 21 male; mean age 37·6 years) were included. The mean SDs of the T‐scores were −1·12 for the lumbar spine and −0·82 for the femoral neck (both P < 0·001). Osteopenia was present in 36%; osteoporosis in 23%. Based on the reference population the expected prevalence was 15% and 1%, respectively. Prevalence of vitamin D deficiency was 50% (defined as a 25‐OH vitamin D level < 50 nmol L−1). Mean self‐reported BPAQ score was 19·4 units (reference interval 19–24). Multiple linear regression analysis showed a significant influence of vitamin D deficiency and bone‐relevant physical exercise score on BMD in patients with EPP. Conclusions The prevalence of osteoporosis and osteopenia is greatly increased in patients with EPP. Alkaline phosphatase (related to vitamin D deficiency) and amount of weight‐bearing exercise are significantly correlated with low BMD in this population.
クロロキンと併用したRIP3を負荷した新しいヒアルロン酸修飾シェル-コアナノ粒子によるPCD経路を介して殺菌結腸癌細胞【Powered by NICT】
Authors: Hou Xueyan, Yang Chengli, Zhang Lijing, Hu Tingting, Sun Dan, Cao Hua, Yang Fan, Guo Gang, Gong Changyang, Zhang Xiaoning, Tong Aiping, Li Rui, Zheng Yu
Journal: Biomaterials (2017)
Dissection of Mechanisms of Realgar Intervening Telomere Protein POT1, TRF1, TRF2 Expression to Regulate Telomere Dynamics in THP-1 Cells
Authors: Rui-Rong Xu, Nan-Xin Song, Xiao-Long Wu, Si-Yuan Cui, Zhen-Zhen Wang, Yan Wang, Xin Wang
Journal: Blood (2016)
Abstract 1: Chemical Biology of Cardiac Regeleration: an Instructive Hydrogel-based Platform for Heart Repair
Authors: Jay W Schneider, Sean C Goetsch, Serge Kyrychenko, Arturo Vegas, Daniel G Anderson, Yi Hong
Journal: Circulation Research (2015)

Regeleration is the myocardium’s natural adaptive remodeling response to implanted biopolymer hydrogels, a new heart failure treatment modality with promising success in early clinical trials. Classified as a medical device capable of long-term myocardial engraftment, implanted hydrogels of varying molecular composition provide mechanical bulking and scaffolding support that can stabilize or reverse adverse ventricular remodeling. Additionally, natural or synthetically designed hydrogels encoding specific bioactivities or signaling functions can directly regulate myocardial biology to mediate heart repair. To gain mechanistic insight into the molecular and cellular biology and biochemistry of the biopolymer-myocardial interface, we studied two clinically relevant hydrogels - seaweed-derived alginate (Alg) and myomatrix (MMx), extracellular matrix molecules prepared from decellularized pig heart - in a mouse model. Alg and MMx differentially activated signal transduction cascades, recruited different cell types and produced distinctive gene expression signatures and patterns of cardiomyocyte hypertrophy, including muscle enhancer factor-2 (MEF2) and fetal gene program (re)activation. Chemically modifying Alg’s backbone structure correspondingly altered myocardium’s biological response, demonstrating the synthetic tunability of this repair process. These observations demonstrate that implanted biopolymer hydrogels drive unexpectedly robust and versatile regelerative responses in myocardium, transducing physical and biochemical signals to the cardiac genome that contribute to hydrogel function, providing a potential therapeutic target for enhancing hydrogel-mediated heart repair without stem cells.
抗血管新生ペプチドナノファイバーによるVEGF媒介角膜血管新生の阻害【Powered by NICT】
Authors: Senturk Berna, Cubuk M. Ozgur, Ozmen M. Cuneyt, Aydin Bahri, O Guler Mustafa, B Tekinay Ayse
Journal: Biomaterials (2016)
Janus Kinase Inhibition By Ruxolitinib Combined with Nilotinib Has Superior Anti-Leukemia Propagating Cells Effect in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Authors: Yuan Kong, Yi-Lin Wu, Yang Song, Min-Min Shi, Ya-Zhen Qin, Yue-Yun Lai, Hao Jiang, Qian Jiang, Xiao-Jun Huang
Journal: Blood (2016)
Incidence and Risk of Delayed Hemolytic Transfusion Reaction in Sickle Cell Disease Patients Based on a Prospective Study
Authors: France Pirenne, David Narbey, Philippe Chadebech, Armand Mekontso-Dessap, Pablo Bartolucci, Claire Rieux, Marc Michel, Sadaf Pakdaman, Rachid Djoudi, Frédéric Galacteros, Anoosha Habibi
Journal: Blood (2016)
A comparison of simple single-item measures and the NCI Common Toxicity Criteria version 3.0 measure of peripheral neuropathy.
Authors: Suneetha Puttabasavaiah, Heshan Liu, Rui Qin, Lisa A. Kottschade, Debra L. Barton, Charles L. Loprinzi, Axel Grothey, Gamini S. Soori, Jeff A. Sloan
Journal: Journal of Clinical Oncology (2012)

1557 Background: Peripheral neuropathy (PN), a common and intrusive side effect of chemotherapy in clinical trials, has been assessed via the clinician-rated common terminology criteria for adverse events (CTCAE) and/or patient-reported outcome (PRO) measures (Morton, ASCO, 2005). We assessed the relative sensitivity of CTCAE and PRO measures for evaluating interventions for preventing and ameliorating CIPN. Methods: Data from285 patients in two prevention trials (N05C3, N04C7) and 432 patients from three intervention trials (N00C3, N01C3, N06CA) were analyzed separately. CTCAE version 3.0 item for neuropathy was compared to 2 NCCTG numerical analogue CIPN items, 6 EORTC CIPN20 individual items, 2 McGill Pain Questionnaire items, and one Brief Pain Inventory item. The sample size provided over 80% power to detect a true Spearman rank correlation of 0.15 assessed the relationship between CTCAE and PRO measures. Results: Results from both the prevention and treatment trials were similar in terms of the relationship between the CTCAE and PRO measures. No correlation coefficients between the CTCAE and any of the PRO items at baseline were above 0.35, with the majority around 0.2. Higher scores for the numbness items were observed than for the CTCAE in 47% of the patients at baseline and 39% during treatment in the treatment trials. Many patients had severe numbness PRO scores but mild CTCAE scores (12%) at baseline and (8%) during treatment in the treatment trials. Results for the numbness and tingling PRO measures were redundant. The correlations of the CTCAE with pain were weak, all below 0.35 at baseline with differences as much as 29 points on average on a 0-100 transformed scale. Conclusions: The CTCAE and PRO measures of PN measure different constructs. The CTCAE includes both functional and ADL/motor aspects which may or may not be related to the singular constructs of pain, numbness, tingling, or adjectival characteristics of pain assessed by the PRO measures. The two measures cannot be used in place of each other.
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
Authors: Robert P Giugliano, Terje R Pedersen, Jeong-Gun Park, Gaetano M De Ferrari, Zbigniew A Gaciong, Richard Ceska, Kalman Toth, Ioanna Gouni-Berthold, Jose Lopez-Miranda, François Schiele, François Mach, Brian R Ott, Estella Kanevsky, Armando Lira Pineda, Ransi Somaratne, Scott M Wasserman, Anthony C Keech, Peter S Sever, Marc S Sabatine
Journal: The Lancet (2017)
マイクロカプセル化GDNFの脳送達はパーキンソン病サルにおける機能的および構造的回復を誘発する【Powered by NICT】
Authors: Garbayo Elisa, Ansorena Eduardo, Lana Hugo, Carmona-Abellan Maria del Mar, Marcilla Irene, Lanciego Jose Luis, Luquin Maria Rosario, Blanco-Prieto Maria Jose
Journal: Biomaterials (2016)
Prognostic Impact of Extent, Severity, and Heterogeneity of Abnormalities on 18F-FDG PET Scans for Suspected Cardiac Sarcoidosis
Authors: Brett W. Sperry, Balaji K. Tamarappoo, Jorge D. Oldan, Omair Javed, Daniel A. Culver, Richard Brunken, Manuel D. Cerqueira, Rory Hachamovitch
Journal: JACC. Cardiovascular imaging (2017)
Dexamethasone Without Antibiotics for Sore Throat
Authors: Svetlozar Sardovski
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Even the Eye Has a Microbiome
Authors: Jeff Lyon
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Critical Role in Bone Marrow Protease-Activated Receptor-2 in the Pathogenesis of Vascular Inflammation and Atherosclerosis in ApoE-Deficient Mice
Authors: Hara Tomoya, Fukuda Daiju, Tanaka Kimie, Higashikuni Yasutomi, Hirata Yoichiro, Yagi Shusuke, Soeki Takeshi, Shimabukuro Michio, Sata Masataka
Journal: Circulation (2016)
HEE moves towards ending “exit exam” status of MRCGP
Authors: Abi Rimmer
Journal: BMJ (2017)

GP trainees who were unable to pass one part of the membership of the Royal College of General Practitioners (MRCGP) assessment may be allowed to re-enter training, Health Education England has said.1

Doctors have previously raised concerns that, unlike in hospital specialties, the MRCGP is an exit examination and a doctor cannot practise as a general practitioner in any capacity without passing it.2

In a response to a consultation on proposals for targeted GP training, HEE outlined its plans for those who …
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation
Authors: Tobias Kessler, Felix Sahm, Ahmed Sadik, Damian Stichel, Anne Hertenstein, Guido Reifenberger, Angela Zacher, Michael Sabel, Ghazaleh Tabatabai, Joachim Steinbach, Ulrich Sure, Dietmar Krex, Anca-L Grosu, Melanie Bewerunge-Hudler, David Jones, Stefan M Pfister, Michael Weller, Christiane Opitz, Martin Bendszus, Andreas von Deimling, Michael Platten, Wolfgang Wick
Journal: Neuro-Oncology (2017)

O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status is a predictive biomarker in glioblastoma. We investigated whether this marker furthermore defines a molecularly distinct tumor subtype with clinically different outcome. We analyzed copy number variation (CNV) and methylation profiles of 1095 primary and 92 progressive isocitrate dehydrogenase wildtype glioblastomas, including paired samples from 49 patients. DNA mutation data from 182 glioblastoma samples of The Cancer Genome Atlas (TCGA) and RNA expression from 107 TCGA and 55 Chinese Glioma Genome Atlas samples were analyzed. Among untreated glioblastomas, MGMT promoter methylated (mMGMT) and unmethylated (uMGMT) tumors did not show different CNV or specific gene mutations, but a higher mutation count in mMGMT tumors. We identified 3 methylation clusters. Cluster 1 showed the highest average methylation and was enriched for mMGMT tumors. Seventeen genes including gastrulation brain homeobox 2 (GBX2) were found to be hypermethylated and downregulated on the mRNA level in mMGMT tumors. In progressive glioblastomas, platelet derived growth factor receptor alpha (PDGFRA) and GLI2 amplifications were enriched in mMGMT tumors. Methylated MGMT tumors gain PDGFRA amplification of PDGFRA, whereas uMGMT tumors with amplified PDGFRA frequently lose this amplification upon progression. Glioblastoma patients surviving <6 months and with mMGMT harbored less frequent epidermal growth factor receptor (EGFR) amplifications, more frequent TP53 mutations, and a higher tumor necrosis factor–nuclear factor-kappaB (TNF-NFκB) pathway activation compared with patients surviving >12 months. MGMT promoter methylation status does not define a molecularly distinct glioblastoma subpopulation among untreated tumors. Progressive mMGMT glioblastomas and mMGMT tumors of patients with short survival tend to have more unfavorable molecular profiles.